Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

Table 2

Comparison of the patients’ backgrounds between the success and failure groups, based on PP analysis (third-line eradication therapy).

	Success group; ( = 22)	Failure group; ( = 26)	value
Age (mean ± S.D.)	64.1 ± 10.0	56.2 ± 13.5	<0.05^∗
Sex (male/female)	11/11	7/19	n.s.^∗∗
BMI^† (mean ± S.D.)	22.0 ± 3.3	22.3 ± 4.0	n.s.^∗
Eradication therapy (RAL/RA)	11/11	13/13	n.s.^∗∗
Success of H. pylori culture (yes/no)^a	8/14	20/5	<0.05^∗∗
Drug resistance, (%)
Amoxicillin	0 (0)	0 (0)	n.s.^∗∗
Clarithromycin	6 (75.0)	17 (81.0)	n.s.^∗∗
Metronidazole	6 (75.0)	16 (76.2)	n.s.^∗∗
Levofloxacin	3 (37.5)	10 (47.6)	n.s.^∗∗
CYP2C19 polymorphism (EM^‡/PM)^b	14/5	19/6	n.s.^∗∗

BMI, body mass index; EM, extensive metabolizer; PM, poor metabolizer; one patient in failure group refused the drug sensitivity test; four patients (three in success group and one in failure group) refused the analysis of CYP2C19 polymorphism; ^∗unpaired -test; ^∗∗chi-square test.